TS 121

Drug Profile

TS 121

Alternative Names: TS 1211; TS-121

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class Antidepressants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 01 May 2017 Phase-II clinical trials in Major depressive disorder (Adjunctive treatment) in USA (PO) (NCT03093025)
  • 31 Mar 2017 Taisho Pharmaceutical plans a phase II trial for Major depressive disorders (Adjunctive therapy) in USA (NCT03093025)
  • 01 Jan 2016 Taisho Pharmaceuticals completes a phase I trial in Major depressive disorders in USA (NCT02448212)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top